Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements from an International Expert Panel

Clinical Infectious Diseases

Volumn 62, Issue 6, 2015, Pages 761-769

  Gupta, Amita ^a   Mathad, Jyoti S ^h   Abdel Rahman, Susan M ⁱ   Albano, Jessica D ^j   Botgros, Radu ^r   Brown, Vikki ^k   Browning, Renee S ^c   Dawson, Liza ^c   Dooley, Kelly E ^b   Gnanashanmugam, Devasena ^c   Grinsztejn, Beatriz ^s   Hernandez DIaz, Sonia ^m   Jean Philippe, Patrick ^d   Kim, Peter ^c   Lyerly, Anne D ^l   Mirochnick, Mark ^o   Mofenson, Lynne M ^e   Montepiedra, Grace ⁿ   Piper, Jeanna ^c   Sahin, Leyla ^g   Savic, Radojka ^p   Smith, Betsy ^c   Spiegel, Hans ^d   Swaminathan, Soumya ^t   Watts, D Heather ^q   White, Amina ^f   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ Children's Mercy Hospital   (United States)

^j Post Approval and Strategic Services   (United States)

^k SYNEOS HEALTH   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m Department of Epidemiology ^*  (United States)

ⁿ CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^o BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q U S DEPARTMENT OF STATE   (United States)

^r EUROPEAN MEDICINES AGENCY   (United Kingdom)

^s Funda??o Oswaldo Cruz   (Brazil)

^t NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

more..

Author keywords

Clinical trials; Latent tuberculosis infection; MDR tuberculosis; Pregnancy; Tuberculosis

Indexed keywords

NEW DRUG; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HIGH RISK PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NATIONAL HEALTH ORGANIZATION; PATIENT PARTICIPATION; PHARMACODYNAMICS; PHARMACOKINETICS; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; REVIEW; TUBERCULOSIS; UNITED STATES; ADULT; BLOOD; CONSENSUS DEVELOPMENT; ETHICS; FEMALE; HIV INFECTIONS; LEGISLATION AND JURISPRUDENCE; MICROBIOLOGY; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; POSTPARTUM PERIOD; PREGNANCY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 84960129843     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ991     Document Type: Review

References (63)

1. World Health Organization. Global tuberculosis report 2015. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 2 December 2015.
2. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health 2014; 2:e710-6.
3. Zumla A, Bates M, Mwaba P. The neglected global burden of tuberculosis in pregnancy. Lancet Glob Health 2014; 2:e675-6.
4. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis 2012; 55:1532-49.
5. Grange J, Adhikari M, Ahmed Y, et al. Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet 2010; 108:181-3.
6. Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis 2004; 4:155-65.
7. Jana N, Barik S, Arora N, Singh AK. Tuberculosis in pregnancy: the challenges for South Asian countries. J Obstet Gynaecol Res 2012; 38:1125-36.
8. Desai M, Phillips-Howard PA, Odhiambo FO, et al. An analysis of pregnancy-related mortality in the KEMRI/CDC health and demographic surveillance system in western Kenya. PLoS One 2013; 8:e68733.
9. Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999; 3:675-80.
10. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012; 185:779-84.
11. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med 2014; 371:1077.
12. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 2001; 25:120-3.
13. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanisticbased approach. Clin Pharmacokinet 2005; 44:989-1008.
14. Food and Drug Administration. Pregnancy and lactation labeling final rule. Available at: http://1.usa.gov/1CpyUFt. Accessed 10 April 2015.
15. Krasula RW, Pernet AG. Comparison of organ-specific toxicity of temafloxacin in animals and humans. Am J Med 1991; 91:38s-41.
16. European Medicine Agency. European Medicines Agency recommends two new treatment options for tuberculosis. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/11/WC500155472.pdf. Accessed 24 November 2013.
17. Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. 2002. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071639.pdf. Accessed 13 March 2014.
18. World Health Organization. Treatment of tuberculosis: guidelines. Geneva, Switzerland: World Health Organization; 2010.
19. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52(RR-11):1-77.
20. Karabay O, Gozdas HT. Should pyrazinamide be preferred in tuberculosis treatment during pregnancy? Indian J Med Res 2013; 138:147.
21. Khan M, Pillay T, Moodley JM, Connolly CA. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15:1857-63.
22. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy 2012; 2012:379271.
23. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26:2039-52.
24. Matsui D. Adherence with drug therapy in pregnancy. Obstet Gynecol Int 2012; 2012:796590.
25. Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis 2015; 211:197-205.
26. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 10 July 2014.
27. World Health Organization Stop TB Partnership. The global plan to stop TB 2011-2015. Transforming the fight: towards elimination of tuberculosis. Available at: http://www.stoptb.org/assets/documents/global/plan/tb-globalplantostoptb2011-2015.pdf. Accessed 15 March 2015.
28. World Health Organization. Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB-and HIV-prevalence settings: 2015 update. Available at: http://www.who.int/tb/publications/2015-ipt-update/en/. Accessed 15 March 2015.
29. Taylor AW, Mosimaneotsile B, Mathebula U, et al. Pregnancy outcomes in HIVinfected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol 2013; doi:10.1155/2013/195637.
30. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
31. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11-20.
32. Mathad JS, Bhosale R, Sangar V, et al. Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting. PLoS One 2014; 9:e92308.
33. Tiam A, Machekano R, Gounder CR, et al. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finDing and isoniazid preventive therapy. J Acquir Immune Defic Syndr 2014; 67: e5-11.
34. Searle C, Coovadia H. Integrating tuberculosis services into a PMTCT HIV programme in South Africa. Int J Tuberc Lung Dis 2013; 17:1247.
35. Uwimana J, Jackson D. Integration of tuberculosis and prevention of mother-tochild transmission of HIV programmes in South Africa. Int J Tuberc Lung Dis 2013; 17:1285-90.
36. Tittle V, Bull L, Boffito M, Nwokolo N. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Clin Pharmacokinet 2015; 54:23-34.
37. Food and Drug Administration. Guidance for industry. Pharmacokinetics in pregnancy-study design, data analysis, and impact on dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/. . ./Guidances/ucm072133.pdf. Accessed 12 March 2014.
38. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15:711-20.
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). 2009. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Multidisciplinary/M3-R2/Step4/M3-R2-Guideline.pdf. Accessed 13 March 2014.
40. International Conference on Harmonisation . Detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2). 2005. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S5/Step4/S5-R2-Guideline.pdf. Accessed 13 March 2014.
41. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). 2011. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S2-R1/Step4/S2R1-Step4.pdf. Accessed 13 March 2014.
42. Chervenak FA, McCullough LB. An ethically justified framework for clinical investigation to benefit pregnant and fetal patients. Am J Bioeth 2011; 11:39-49.
43. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues 2013; 23:e39-45.
44. Code of Federal Regulation, Title 45 Public Welfare, Department of Health and Human Services, part 46, Protection of Human Subjects, Subpart B-Additional Protections for Pregnant Women, Human fetuses and Neonates Involved in Research [volume No 66] Federal Register [Page 56779] (2001) (45 CFR 46, section 46.204). Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html. Accessed 1 December 2015.
45. Lyerly AD, Mitchell LM, Armstrong EM, et al. Risk and the pregnant body. Hastings Cent Rep 2009; 39:34-42.
46. Lyerly AD, Little MO, Faden RR. Reframing the framework: toward fair inclusion of pregnant women as participants in research. Am J Bioeth 2011; 11:50-2.
47. Kass NE, Taylor HA, King PA. Harms of excluDing pregnant women from clinical research: the case of HIV-infected pregnant women. J Law Med Ethics 1996; 24:36-46.
48. Lyerly AD, Little MO, Faden RR. Pregnancy and clinical research. Hastings Cent Rep 2008; 38:inside back cover.
49. Food and Drug Administration. Guidance for industry. Pulmonary tuberculosis: developing drugs for treatment. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm373580.pdf. Accessed 3 March 2015.
50. Food and Drug Administration. Guidance for industry. Pharmacokinetics in pregnancy-study design, data analysis, and impact on dosing and labelling. 2004. Available at: http://www.fda.gov/downloads/Drugs/. . ./Guidances/ucm072133. pdf. Accessed 12 March 2014.
51. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs:III. Revised policy on inclusion of women of childbearing potential in Clinical Trials. Federal Register 1993; 58(139):39407. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126835.pdf. Accessed 11 December 2015.
52. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003307.pdf. Accessed 12 March 2014.
53. Wyska E, Jusko WJ. Approaches to pharmacokinetic/pharmacodynamic modeling during pregnancy. Semin Perinatol 2001; 25:124-32.
54. Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol 2014; 54:53-69.
55. Food and Drug Administration. Reviewer guidance: evaluating the risks of drug exposure in human pregnancies. 2005. Available at: http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm133359.pdf. Accessed 13 March 2014.
56. Sheffield JS SD, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis 2014; 59(suppl 7):S437-44.
57. McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis 2015; 211(suppl 3):S115-25.
58. FDA. Guidance for industry. Exposure-response relationships-study design, drug analysis, and regulatory applications. 2003. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm. Accessed 29 October.
59. Brown V, Albano J, Phelps K, Whitehouse J. Use of pregnancy registries for risk management. In: Sietsema WK, Sprafka JM, eds. Risk management principles for devices and pharmaceuticals: global perspectives on the benefit: risk assessment of medicinal products. 1st ed. Rockville, MD: Regulatory Affairs Professional Society, 2012:95-100.
60. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. 2005. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/11/WC500011303.pdf. Accessed 13 March 2014.
61. Shapiro RL HM, Ogwu A, et al. Antiretroviral regimens in pregnancy and breastfeeDing in Botswana. N Engl J Med 2010; 362:2282-94.
62. Chasela CS HM, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-81.
63. International Maternal Pediatric Adolescent AIDS Clinical Trials Network. Studies. Available at: http://impaactnetwork.org/studies/index.asp#devel. Accessed 1 December 2015.